Functional Respiratory Imaging Study (DARWiIN)
Фаза 3
Завершено
NCT04876677
| Заболевание | Chronic Obstructive Pulmonary Disease |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Chiesi Farmaceutici S.p.A. |
|---|
| Статус | Завершено |
|---|
| Участники | 25 участн. |
|---|
| Вмешательство | Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium (BDP/FF/GB) |
|---|
| Дата начала | 18.05.2021 |
|---|
| Дата завершения | 3.01.2022 |
|---|
| Публикация результатов | 9.04.2026 |
|---|
Кратко
The objective of this clinical study was to evaluate the tolerability, safety, and efficacy of stepping up from fluticasone propionate (FP)/salmeterol (SLM) dry-powder inhaler (DPI) (SERETIDE™ DISKUS™) to extrafine beclometasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) DPI (CHF5993) and to assess its effect on airway geometry and lung ventilation in subjects with advanced Chronic Obstructive Pulmonary Disease (COPD). Primary Objectives: * Untrimmed siVaw for distal region at TLC - actual value for V2 pre-dose and V3 pre-dose * Trimmed siRaw for distal region at TLC - actual value for V2 pre-dose and V3 pre-dose Secondary Objectives: * Untrimmed siVaw for distal region at TLC and FRC - actual value for V2 pre-dose, V2 post-dose, V3 pre-dose and V3 post-dose * Trimmed siRaw for distal region at TLC and FRC - actual value for V2 pre-dose, V2 post-dose, V3 pre-dose and V3 post-dose * Safety assessment through the evaluation of treatment-emergent adverse events (TEAEs).
Untrimmed Airway Volume (siVaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose and V3 Pre-dose
V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days) · liters
| CHF5993 DPI 100/6/12.5 μg - PP Population | 1.4088 ± 0.6647 liters |
|---|
| CHF5993 DPI 100/6/12.5 μg - PP Population | 1.3550 ± 0.6014 liters |
|---|
| p-value | = 0.4521 |
| Adjusted Mean Change | -3.81 (95% CI -13.44–6.89) |
Trimmed Airway Volume (siRaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose and V3 Pre-dose
V2 pre-dose (i.e. baseline, assessed at week 6 ± 2 days), V3 pre-dose (assessed at week 12 ± 2 days) · cmH₂O·s
| CHF5993 DPI 100/6/12.5 μg - PP Population | 0.7160 ± 0.4034 cmH₂O·s |
|---|
| CHF5993 DPI 100/6/12.5 μg - PP Population | 0.8492 ± 0.5947 cmH₂O·s |
|---|
| p-value | = 0.4871 |
| Adjusted Mean Change | 11.95 (95% CI -19.67–56.02) |
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.